Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

(Reuters) -Merck has licensed an early-stage cancer drug from a China-based biotech in an up to $3.3 billion deal, two months ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Merck (MRK) announced that the European Commission (EC) has approved two new indications for Keytruda, Merck’s anti-PD-1 therapy, in gynecologic cancers. The first approval is for Keytruda ...

Merck, known as MSD outside of the United States and Canada, announced that the European Commission (EC) has approved two new indications for Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Merck’s (NYSE:MRK) blockbuster cancer therapy Keytruda (pembrolizumab ... who have not received prior definitive therapy. The EC approvals are based on results from two late-stage trials ...

The firm sees new growth levers to offset the Keytruda loss of exclusivity. Merck’s vaccine franchise is a “high impact contributor,” the analyst tells investors in a research note.

Merck Research Laboratories. "These approvals underscore the continued expansion of the use of KEYTRUDA in diverse patient populations and treatment settings with utility of KEYTRUDA ranging from ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless of ...